Healthcare provider profile · identity verified

Kendra Sherier, MD

Allopathic & Osteopathic Physicians|Family Medicine · SAPULPA, OK · NPI 1659834950

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Kendra Sherier, MD received $176.71 in general payments during 2025 across 2 reported records.

Boston Scientific Corporation accounted for 80.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 454 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$176.71

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boston Scientific Corporation	Unresolved — no canonical attribution shown	$141.59	80.1%	1	2025
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$35.12	19.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$176.71	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
WATCHMAN FLX Normalized: watchman flx	Device	Boston Scientific Corporation	$141.59	1	2025
Source payment records 2025-04-08 · Boston Scientific Corporation · $141.59 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	454	85

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	589	104
Lisinopril	Lisinopril	552	109
Rosuvastatin Calcium	Rosuvastatin Calcium	537	110
Jardiance	Empagliflozin	454	85
Amlodipine Besylate	Amlodipine Besylate	430	77
Fluticasone Propionate	Fluticasone Propionate	410	102
Losartan Potassium	Losartan Potassium	401	74
Ozempic	Semaglutide	386	77
Metformin Hcl	Metformin Hcl	374	77
Omeprazole	Omeprazole	366	75
Metoprolol Succinate	Metoprolol Succinate	350	62
Synthroid	Levothyroxine Sodium	339	53
Hydrochlorothiazide	Hydrochlorothiazide	260	44
Gabapentin	Gabapentin	257	56
Pantoprazole Sodium	Pantoprazole Sodium	226	42
Montelukast Sodium	Montelukast Sodium	224	39
Potassium Chloride	Potassium Chloride	206	38
Tamsulosin Hcl	Tamsulosin Hcl	190	38
Trazodone Hcl	Trazodone Hcl	185	34
Famotidine	Famotidine	183	36
Clopidogrel	Clopidogrel Bisulfate	178	25
Furosemide	Furosemide	174	38
Eliquis	Apixaban	163	30
Duloxetine Hcl	Duloxetine Hcl	162	31
Fenofibrate	Fenofibrate Nanocrystallized	138	28
Carvedilol	Carvedilol	131	33
Ezetimibe	Ezetimibe	122	19
Sertraline Hcl	Sertraline Hcl	121	27
Droplet Pen Needle	Pen Needle, Diabetic	116	24
Oxybutynin Chloride	Oxybutynin Chloride	114	20
Spiriva Respimat	Tiotropium Bromide	113	23
Tizanidine Hcl	Tizanidine Hcl	111	24
Simvastatin	Simvastatin	100	16
Escitalopram Oxalate	Escitalopram Oxalate	97	17
Novolog Flexpen	Insulin Aspart	97	26
Wixela Inhub	Fluticasone Propion/Salmeterol	95	15
Ibuprofen	Ibuprofen	92	15
Albuterol Sulfate Hfa	Albuterol Sulfate	89	35
Alogliptin	Alogliptin Benzoate	89	21
Alendronate Sodium	Alendronate Sodium	86	15
Nifedipine Er	Nifedipine	86	24
Tresiba Flextouch U-100	Insulin Degludec	86	13
Atenolol	Atenolol	77	14
Diclofenac Sodium	Diclofenac Sodium	77	36
Meloxicam	Meloxicam	77	16
Fluoxetine Hcl	Fluoxetine Hcl	73	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	71	suppressed
Myrbetriq	Mirabegron	71	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	70	12
Allopurinol	Allopurinol	68	13
Donepezil Hcl	Donepezil Hcl	65	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	63	14
Baclofen	Baclofen	58	13
Bupropion Xl	Bupropion Hcl	58	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	57	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	56	16
Finasteride	Finasteride	53	suppressed
Lidocaine	Lidocaine	51	13
Buspirone Hcl	Buspirone Hcl	50	13
Pregabalin	Pregabalin	49	suppressed
Metformin Hcl Er	Metformin Hcl	48	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	45	12
Hydroxyzine Hcl	Hydroxyzine Hcl	44	suppressed
Citalopram Hbr	Citalopram Hydrobromide	43	suppressed
Hydralazine Hcl	Hydralazine Hcl	40	suppressed
Nitroglycerin	Nitroglycerin	39	suppressed
Glipizide Er	Glipizide	38	suppressed
Aripiprazole	Aripiprazole	37	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	37	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	37	27
Diltiazem 24hr Er	Diltiazem Hcl	36	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	36	suppressed
Spironolactone	Spironolactone	36	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	36	suppressed
Bupropion Hcl Sr	Bupropion Hcl	35	suppressed
Celecoxib	Celecoxib	35	suppressed
Tresiba Flextouch U-200	Insulin Degludec	35	suppressed
Chlorthalidone	Chlorthalidone	34	suppressed
Clonidine Hcl	Clonidine Hcl	34	suppressed
Propranolol Hcl	Propranolol Hcl	34	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	32	suppressed
Levemir Flexpen	Insulin Detemir	30	19
Ondansetron Odt	Ondansetron	29	15
Folic Acid	Folic Acid	28	suppressed
Trulicity	Dulaglutide	26	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	25	suppressed
Midodrine Hcl	Midodrine Hcl	25	suppressed
Entresto	Sacubitril/Valsartan	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Doxepin Hcl	Doxepin Hcl	22	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	22	16
Naproxen	Naproxen	21	suppressed
Prednisone	Prednisone	21	14
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	20	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	20	suppressed
Humalog Kwikpen U-100	Insulin Lispro	19	suppressed
Nebivolol Hcl	Nebivolol Hcl	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Tramadol Hcl	Tramadol Hcl	19	suppressed
Valacyclovir	Valacyclovir Hcl	17	suppressed
Estradiol	Estradiol	16	suppressed
Levetiracetam	Levetiracetam	16	suppressed
Promethazine Hcl	Promethazine Hcl	16	suppressed
Solifenacin Succinate	Solifenacin Succinate	16	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	16	suppressed
Ventolin Hfa	Albuterol Sulfate	16	suppressed
Minoxidil	Minoxidil	15	suppressed
Mounjaro	Tirzepatide	15	suppressed
Prolia	Denosumab	15	suppressed
Terazosin Hcl	Terazosin Hcl	15	suppressed
Verapamil Er	Verapamil Hcl	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	13	13
Captopril	Captopril	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Verapamil Hcl	Verapamil Hcl	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Dulera	Mometasone/Formoterol	12	suppressed
Pentoxifylline	Pentoxifylline	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	12	suppressed
Fluconazole	Fluconazole	11	suppressed
Lactulose	Lactulose	11	suppressed
Latanoprost	Latanoprost	11	suppressed
Metolazone	Metolazone	11	suppressed
Theophylline Er	Theophylline Anhydrous	11	suppressed
Tretinoin	Tretinoin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$176.71 · 2 records	Boston Scientific Corporation	WATCHMAN FLX	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error